137 related articles for article (PubMed ID: 16125599)
1. Breast cancer: what's HER-2/neu got to do with it?
Lenahan C; Dennis C; Isakovich NV; Pories SE
Curr Surg; 2005; 62(5):459-64. PubMed ID: 16125599
[No Abstract] [Full Text] [Related]
2. The prognostic and predictive values of circulating HER-2/neu extracellular domain in patients with metastatic breast cancer.
Abu-Khalaf MM; Harris L
Breast Cancer Res Treat; 2009 Apr; 114(3):513-5. PubMed ID: 18677560
[No Abstract] [Full Text] [Related]
3. Serum EGFR and serum HER-2/neu are useful predictive and prognostic markers in metastatic breast cancer patients treated with metronomic chemotherapy.
Sandri MT; Johansson HA; Zorzino L; Salvatici M; Passerini R; Maisonneuve P; Rocca A; Peruzzotti G; Colleoni M
Cancer; 2007 Aug; 110(3):509-17. PubMed ID: 17559147
[TBL] [Abstract][Full Text] [Related]
4. [An investigation of extracellular HER-2/NEU domain level in blood serum from breast cancer patients].
Korytova LI; Masliukova EA; Ovchinnikov IV; Filipenko MO; Korytov OV; Kudaĭbergenova AG
Vopr Onkol; 2010; 56(1):62-5. PubMed ID: 20361618
[TBL] [Abstract][Full Text] [Related]
5. Elevated plasma tissue inhibitor of metalloproteinase-1 level predicts decreased response and survival in metastatic breast cancer.
Lipton A; Ali SM; Leitzel K; Demers L; Evans DB; Hamer P; Brown-Shimer S; Pierce K; Carney W
Cancer; 2007 May; 109(10):1933-9. PubMed ID: 17407159
[TBL] [Abstract][Full Text] [Related]
6. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401.
; Tanner M; Isola J; Wiklund T; Erikstein B; Kellokumpu-Lehtinen P; Malmström P; Wilking N; Nilsson J; Bergh J
J Clin Oncol; 2006 Jun; 24(16):2428-36. PubMed ID: 16682728
[TBL] [Abstract][Full Text] [Related]
7. Serial serum c-erbB-2 levels in patients with breast carcinoma.
Volas GH; Leitzel K; Teramoto Y; Grossberg H; Demers L; Lipton A
Cancer; 1996 Jul; 78(2):267-72. PubMed ID: 8674002
[TBL] [Abstract][Full Text] [Related]
8. Is circulating HER-2 more than just a tumor marker?
Baselga J
Clin Cancer Res; 2001 Sep; 7(9):2605-7. PubMed ID: 11555569
[No Abstract] [Full Text] [Related]
9. Selecting endocrine therapy for breast cancer: what role does HER-2/neu status play?
Prowell TM; Armstrong DK
Semin Oncol; 2006 Dec; 33(6):681-7. PubMed ID: 17145348
[TBL] [Abstract][Full Text] [Related]
10. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
[TBL] [Abstract][Full Text] [Related]
11. Changes over time of extracellular domain of HER2 (ECD/HER2) serum levels have prognostic value in metastatic breast cancer.
Bramwell VH; Doig GS; Tuck AB; Wilson SM; Tonkin KS; Tomiak A; Perera F; Vandenberg TA; Chambers AF
Breast Cancer Res Treat; 2009 Apr; 114(3):503-11. PubMed ID: 18437556
[TBL] [Abstract][Full Text] [Related]
12. Role of endocrine responsiveness and HER2/neu overexpression in inflammatory breast cancer treated with multimodality preoperative therapy.
D'Alessandro C; Dellapasqua S; Orlando L; Santoro L; Maisonneuve P; Torrisi R; Balduzzi A; Scarano E; Ghisini R; Peruzzotti G; Goldhirsch A; Colleoni M
Breast J; 2008; 14(5):435-41. PubMed ID: 18821931
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of HER-2/neu amplification and other biological markers as predictors of response to neoadjuvant anthracycline-based chemotherapy in primary breast cancer: the role of anthracycline dose intensity.
Bozzetti C; Musolino A; Camisa R; Bisagni G; Flora M; Bassano C; Martella E; Lagrasta C; Nizzoli R; Personeni N; Leonardi F; Cocconi G; Ardizzoni A
Am J Clin Oncol; 2006 Apr; 29(2):171-7. PubMed ID: 16601438
[TBL] [Abstract][Full Text] [Related]
14. The influence of serum HER-2 levels and HER-2 codon 655 polymorphism on breast cancer outcome.
Papadopoulou E; Tripsianis G; Anagnostopoulos K; Tentes I; Kakolyris S; Galazios G; Sivridis E; Simopoulos K; Kortsaris A
Neoplasma; 2008; 55(2):113-21. PubMed ID: 18237248
[TBL] [Abstract][Full Text] [Related]
15. Latest studies hint at survival advantage with aromatase inhibitors in early breast cancer.
Tuma RS
J Natl Cancer Inst; 2006 Jan; 98(2):86-7. PubMed ID: 16418506
[No Abstract] [Full Text] [Related]
16. Twelve-year mortality results of a randomized trial of 2 versus 5 years of adjuvant tamoxifen for postmenopausal early-stage breast carcinoma patients (SITAM 01).
Alliot C
Cancer; 2006 Jul; 107(1):215; author reply 215-6. PubMed ID: 16691577
[No Abstract] [Full Text] [Related]
17. HER-2/neu serum levels vis-à-vis hormonal response in metastatic breast cancer.
Panasci LC
J Clin Oncol; 2002 Aug; 20(15):3357; author reply 3357. PubMed ID: 12149314
[No Abstract] [Full Text] [Related]
18. Commentary: can circulating HER-2 extracellular domain predict response to trastuzumab in HER-2-negative breast cancer?
Esteva FJ
Oncologist; 2008 Apr; 13(4):370-2. PubMed ID: 18448550
[No Abstract] [Full Text] [Related]
19. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group.
Kyndi M; Sørensen FB; Knudsen H; Overgaard M; Nielsen HM; Overgaard J;
J Clin Oncol; 2008 Mar; 26(9):1419-26. PubMed ID: 18285604
[TBL] [Abstract][Full Text] [Related]
20. Do biomarker changes during neoadjuvant endocrine therapy reflect breast tumor receptor status?
Dickler M
Nat Clin Pract Oncol; 2005 Oct; 2(10):498-9. PubMed ID: 16205767
[No Abstract] [Full Text] [Related]
[Next] [New Search]